Literature DB >> 8661958

Skeletal effects of calcitonin treatment and withdrawal in ovariectomized rats.

Y Shen1, M Li, T J Wronski.   

Abstract

The study was designed to determine, by histomorphometric techniques, bone changes as a function of time during long-term treatment with salmon calcitonin (CT) and after withdrawal of the hormone in ovariectomized (OVX) rats. Groups of OVX rats were treated with vehicle alone or CT on alternate days for 30, 60, or 90 days. Additional groups of sham-operated control rats were treated with vehicle alone. Rats from each of the three groups were sacrificed at each time point. All treatments in the remaining rats were then terminated at 90 days, followed by sacrifice of rats from each group at 30 and 60 days after withdrawal of vehicle or CT treatment. The proximal tibia from each animal was processed undecalcified for quantitative bone histomorphometry. Compared with control rats, the proximal tibiae of vehicle-treated OVX rats were characterized by cancellous osteopenia and significant increases in osteoclast surface, osteoblast surface, mineralizing surface, mineral apposition rate, and bone formation rate. CT treatment of OVX rats partially prevented cancellous bone loss by approximately 50% and significantly decreased most of the above indices of bone turnover relative to vehicle-treated OVX rats. However, soon after withdrawal of CT, OVX rats previously treated with the hormone exhibited rapid loss of cancellous bone associated with increased bone turnover. These results in an animal model of estrogen depletion suggest that early postmenopausal women who are withdrawn from prophylactic CT treatment may be at high risk for subsequent bone loss.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8661958     DOI: 10.1007/bf02508646

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  31 in total

1.  Nasal calcitonin for treatment of established osteoporosis.

Authors:  K Overgaard; B J Riis; C Christiansen; J Pødenphant; J S Johansen
Journal:  Clin Endocrinol (Oxf)       Date:  1989-04       Impact factor: 3.478

2.  Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.

Authors:  G F Mazzuoli; M Passeri; C Gennari; S Minisola; R Antonelli; C Valtorta; E Palummeri; G F Cervellin; S Gonnelli; G Francini
Journal:  Calcif Tissue Int       Date:  1986-01       Impact factor: 4.333

3.  Menopausal changes in bone remodeling.

Authors:  R P Heaney; R R Recker; P D Saville
Journal:  J Lab Clin Med       Date:  1978-12

4.  Effect of salcatonin given intranasally on early postmenopausal bone loss.

Authors:  K Overgaard; B J Riis; C Christiansen; M A Hansen
Journal:  BMJ       Date:  1989-08-19

5.  Effect of body weight on osteopenia in ovariectomized rats.

Authors:  T J Wronski; P A Schenck; M Cintrón; C C Walsh
Journal:  Calcif Tissue Int       Date:  1987-03       Impact factor: 4.333

6.  An evaluation of antibodies and clinical resistance to salmon calcitonin.

Authors:  F R Singer; J P Aldred; R M Neer; S M Krane; J T Potts; K J Bloch
Journal:  J Clin Invest       Date:  1972-09       Impact factor: 14.808

7.  Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats.

Authors:  T J Wronski; C F Yen; K S Scott
Journal:  J Bone Miner Res       Date:  1991-04       Impact factor: 6.741

8.  Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.

Authors:  J Y Reginster; D Denis; R Deroisy; M P Lecart; M De Longueville; B Zegels; N Sarlet; P Noirfalisse; P Franchimont
Journal:  J Bone Miner Res       Date:  1994-01       Impact factor: 6.741

9.  Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease.

Authors:  F Levy; R Muff; S Dotti-Sigrist; M A Dambacher; J A Fischer
Journal:  J Clin Endocrinol Metab       Date:  1988-09       Impact factor: 5.958

10.  Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis.

Authors:  G Kollerup; A P Hermann; K Brixen; B E Lindblad; L Mosekilde; O H Sørensen
Journal:  Calcif Tissue Int       Date:  1994-01       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.